---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-056807"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:42:55.904066+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# InMed amends ATM equity offering agreement with H.C. Wainwright

## Summary
- Amendment to April 2022 at-the-market offering agreement with H.C. Wainwright & Co.
- Settlement cycle updated to T+1 (first trading day) to reflect current market rules.
- New data privacy compliance representation added; $50k cap on agent's counsel fees reimbursed.
- Company to file a prospectus supplement and deliver customary closing deliverables on June 27, 2024.
- Prior letter agreements from October 2023 and June 2024 remain effective unless conflicting with amended ATM.

## SEC filing metadata
- accession: 0001213900-24-056807
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024056807/0001213900-24-056807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024056807/ea0208584-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-056807
- JSON: https://secwatch.observer/filing/0001213900-24-056807.json
- Plain text: https://secwatch.observer/filing/0001213900-24-056807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.